Published in final edited form as:

Bioorg Chem. 2009 October ; 37(5): 149–161. doi:10.1016/j.bioorg.2009.06.001.

Mechanisms of Catalysis and Inhibition Operative in the Arginine Deiminase from the Human Pathogen *Giardia lamblia*⁺

Zhimin Li^a, Liudmila Kulakova^b, Ling Li^a, Andrey Galkin^b, Zhiming Zhao^a, Markus Knipp^c, Theodore E. Nash^d, Patrick S. Mariano^a, Osnat Herzberg^b, and Debra Dunaway-Mariano^{a,*}

^aDepartment of Chemistry and Chemical Biology, University of New Mexico, Albuquerque, New Mexico 87131, USA

^bThe Center for Advanced Research in Biotechnology, University of Maryland Biotechnology Institute, Rockville, Maryland 20850, USA

^cDepartment of Chemistry, University of Arizona, Tucson, Arizona 85721, USA

^dLaboratory of Parasitic Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA

Abstract

Giardia lamblia arginine deiminase (GIAD), the topic of this paper, belongs to the hydrolase branch of the guanidine-modifying enzyme superfamily, whose members employ Cys-mediated nucleophilic catalysis to promote deimination of L-arginine and its naturally occurring derivatives. *G. lamblia* is the causative agent in the human disease giardiasis. The results of RNAi/antisense RNA gene-silencing studies reported herein indicate that GIAD is essential for *G. lamblia* trophozoite survival and thus, a potential target for the development of therapeutic agents for the treatment of giardiasis. The homodimeric recombinant protein was prepared in *E. coli* for in-depth biochemical characterization. The 2-domain GIAD monomer consists of a N-terminal domain that shares an active site structure (depicted by an *in-silico* model) and kinetic properties (determined by steady-state and transient state kinetic analysis) with its bacterial AD counterparts, and a C-terminal domain of unknown fold and function. GIAD was found to be active over a wide pH range and to accept L-arginine, L-arginine ethyl ester, *N*^α-benzoyl-L-arginine, and *N*^ω-amino-L-arginine as substrates but not agmatine, L-homoarginine, *N*^α-benzoyl-L-arginine ethyl ester or a variety of arginine-containing peptides. The intermediacy of a Cys424-alkylthiuronium ion covalent enzyme adduct was demonstrated and the rate constants for formation ($k_1 = 80 \text{ s}^{-1}$) and hydrolysis ($k_2 = 35 \text{ s}^{-1}$) of the intermediate were determined. The comparatively lower value of the steady state rate constant ($k_{\text{cat}} = 2.6 \text{ s}^{-1}$), suggests that a step following citrulline formation is rate-limiting. Inhibition of GIAD using Cys directed agents was briefly explored. *S*-nitroso-L-homocysteine was shown to be an active site directed, irreversible inhibitor whereas *N*^ω-cyano-L-

⁺Supported by NIH grant AI059733 to O.H., P.S.M and D. D.-M.

^{*}To whom correspondence should be addressed: Department of Chemistry and Chemical Biology, MSC03 2060, 1 University of New Mexico, Albuquerque, New Mexico 87131, dd39@unm.edu; Fax: 505-277-6202; Tel: 505-277-3383.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

arginine did not inhibit GIAD but instead proved to be an active site directed, irreversible inhibitor of the *Bacillus cereus* AD.

Keywords

L-arginine deiminase; nucleophilic catalysis; L-arginine dehydrolase pathway; mechanism-based inhibition; *Giardia lamblia*

1. Introduction

L-Arginine is degraded by specialized Archaea (e.g., *Korarchaeum cryptofilum*, *Thermoplasma acidophilum*, and *Sulolobus tokodaii*), Bacteria (e.g., *Alistipes putredinis*, *Rhizobium etli*, *Pseudomonas aeruginosa* and *Bacillus cereus*) and amitochondriate parasitic protists (e.g., *Trichomonas vaginalis*, *Chlamydomonas reinhardtii*, *Hexamita inflate* and *Giardia lamblia*) via the arginine dihydrolase (ADH) pathway to generate ATP under anaerobic conditions [1,2]. The ADH pathway consists of three steps, involving (a) hydrolysis of L-arginine (L-Arg) to L-citrulline and ammonia catalyzed by arginine deiminase (AD, EC 3. 5. 3. 6), (b) carbamoyl group transfer from L-citrulline to orthophosphate catalyzed by ornithine carbamoyltransferase (OTC, EC 2.1.3.3) and (c) phosphoryl transfer from carbamoyl phosphate to ADP catalyzed by carbamate kinase (CK, EC 2.7.2.2).

Arginine deiminase (AD) belongs to the guanidine-modifying enzyme superfamily. Members of this family catalyze nucleophilic substitution reactions at the guanidinium carbon atom of L-Arg and its derivatives [3]. The family is divided into the hydrolase branch and the transferase branch. Members of the hydrolase branch include AD, peptidylarginine deiminase (PAD), agmatine deiminase (AgD) and N^{ω} , N^{ω} -dimethylarginine dimethylamidohydrolase (DDAH). The reactions catalyzed by these enzymes (see Fig. 1A) follow a common chemical pathway that involves the intermediacy of a Cys alkyl-thiuronium ion (see Fig. 1B). The catalytic site common to the hydrolases consists of a conserved Cys, which functions in nucleophilic catalysis, a conserved His that participates in acid/base catalysis, and two carboxylate residues that bind the substrate guanidinium group (Fig. 1B). The hydrolases are distinguished on the basis of stringent substrate specificity, which derives from the special tailoring of the binding site for recognition of the appropriate physiological substrate.

The folds and active sites of four representative hydrolases are presented in Fig. 2. The segments of the respective catalytic scaffolds and the substrate binding and catalytic residues positioned on these segments are identified in Fig. 2 by using coloring scheme. Comparison of the hydrolases represented in the figure reveals the divergence in structure that has occurred to achieve substrate specificity in each functional family while conserving the catalytic mechanism of the superfamily. For example, the active site of AgDI cannot accommodate the $C(\alpha)COO^-$ of L-Arg owing to an unfavorable steric and electrostatic interaction that would occur with the side chain of Glu214 (Fig. 2B) [4,5]. Conversely, agmatine does not substitute for L-Arg as an AD substrate as a result of the missing $C(\alpha)COO^-$ group that is required to balance the positively charged side chains of the AD

active site residues Arg243 and Arg185 (Fig. 2A) [6–8]. Likewise, the active sites of AD and DDAH have diverged to complement the $+H_2N=C-NH_2$ unit of L-Arg and the $+H_2N=C-N(CH_3)_2$ unit of N^0 , N^0 -dimethyl-L-arginine, respectively (compare Fig. 2A and 2B) [9,10]. The loops that restrict the entrance of the bacterial AD active site (Fig. 2A) preclude the binding of the Arg side chain of the PAD protein substrate. In Fig. 3A is shown the *P. aeruginosa* AD modeled with the PAD active site Arg-containing peptide ligand to illustrate the steric clash anticipated to occur with the backbone of an Arg-peptidyl substrate. The absence of the active site gating loops in the PAD structure [11] (Fig. 2D) is consistent with PAD's preference for a protein substrate.

The work reported in this paper focuses on the AD from *Giardia lamblia* (GIAD) (ExPasy accession A8BPH7) [12]. *G. lamblia* is a flagellated protozoan that, when ingested by the consumption of contaminated water or food, infects the human gut and causes the disease giardiasis [13]. The gut provides *G. lamblia* with an ample supply of L-Arg for energy production via the ADH pathway. In addition to its role as the first catalyst in this pathway, GIAD appears to facilitate *G. lamblia* colonization through neutralization of the host immune system. Specifically, GIAD was found to catalyze the deimination of the Arg side chain in the conserved CRGKA cytoplasmic tails of *G. lamblia* variant-specific surface proteins (VSPs) [14]. It was proposed that VSP citrullination influences antigenic switching and antibody-mediated cell death. Earlier, it was reported that AD is among 16 immunodominant proteins in *G. lamblia* [15] and in a recent study it was shown that upon contact with human epithelial cells *G. lamblia* releases AD, which in turn serves to diminish NO production and hence, the host immune response [16].

As part of an ongoing program to identify *G. lamblia* enzymes for the development of therapeutic agents, we selected GIAD for target validation, structure determination, kinetic characterization and inhibitor testing. Firstly, RNAi/antisense RNA silencing experiments were carried out to show that GIAD is essential for trophozoite survival. Secondly, a comprehensive biochemical study was carried out to define AD quaternary structure, catalysis, substrate specificity and inhibition by Cys-modifying substrate analogs. The results of this study are presented and discussed below.

2. Materials and Methods

2.1. Materials

L-Arginine, L-citrulline, L-homoarginine, agmatine, N^0 -benzoyl-L-arginine ethyl ester (BAEE) and SFLLRN-amide oligopeptide were purchased from Sigma-Aldrich, N^0 -benzoyl-L-arginine, and L-arginine ethyl ester were obtained from Acros (Hampton, NH). Oligopeptides RAD, RASD and CRGKA were purchased from EZBiolab, Inc.. N^0 -amino-L-arginine was from Alexis Biochemicals (ALX-106-014). Molecular biological materials were purchased from Invitrogen. N^0 -Amino-L-citrulline was a gift from Dr. S. Bruce King of the Department of Chemistry at Wake Forest University. Recombinant *P. aeruginosa* AD (PaAD) was prepared as described in reference [6]. Recombinant *Escherichia coli* AD (EcAD), *Bacillus cereus* AD (BcAD), *Burkholderia mallei* (BmAD) were prepared as described in reference [17]. S-nitroso-L-homocysteine was prepared as described in

reference [18]. (S)-2-amino-4-(Z)-2-cyanoguanidino-butanoic acid was prepared by using a modification of the procedure reported by Wagenaar and Kerwin [19].

2.2. DNA preparation

The trophozoites of the *G. lamblia* isolate WB, clone 1267, were grown axenically at 37 °C in TYI-S-33 medium contained in glass tubes [20]. When monolayers were formed, trophozoites were detached from the surface by chilling on ice for 30 min, harvested by centrifugation at 2000 rpm for 10 min, and washed twice with phosphate buffered saline. The pellet was then used for genomic DNA preparation with the DNA Stat kit (Stratagene).

2.3. Arginine Deiminase Gene Cloning, Expression and Protein Preparation

The AD gene from *G. lamblia* isolate WB clone 1267 was amplified using *PfuTurbo* DNA polymerase (Stratagene), genomic DNA, and 5'- and 3'-end primers as follows: forward: 5'-gagaacctgtacttccagggtatgactgacttctccaaggataagagaag-3' and reverse: 5'-ggggacaagtgttacaaaaagcaggctcgagaacctgtacttccag-3'. The pMBP_AD vector expressing the MBP fusion was constructed using the technique reported by Nallamsetty et al. [21]. The resulting PCR fragment was used as the template for PCR amplification with primers 5'-gagaacctgtacttccagggtatgactgacttctccaaggataagagaag-3' (AD_FOR2) and AD_REV. The AD_FOR2 primer is designed to anneal to the sequence encoding TEV protease cleavage site and add an attB1 recognition site to the end of the amplicon. The resulting PCR fragment was inserted into pDNOR221 (Invitrogen) by recombinational cloning with BP clonase mix using the standard Gateway protocol (Invitrogen). The nucleotide sequence of the entry clone pAD221 was verified by DNA sequencing. The His₆MBP_AD (pMBP_AD) fusion protein expression vector was constructed using the LR clonase enzyme mix (Invitrogen) to recombine the AD ORF from the pAD221 entry vector with the destination vector pDEST-His MBP. Site-directed mutants were prepared from the pMBP_AD using commercial primers and the QuikChange site-directed mutagenesis kit (Stratagene). *E. coli* BL21 Star(DE3) cells transformed with the AD expression vector were grown overnight at 37°C in Luria broth (LB) in the presence of 50 µg/mL carbenicillin with shaking at 180 rpm. The cells were harvested by centrifugation (6500 rpm, 15 min, 4°C) yielding ca. 3 g cells/L of culture media. The cell pellets were suspended in ice cold buffer A (50 mM K⁺HEPES containing 1 mM DTT, pH 7.5; 1 gm/10 mL) and then passed through a French Press at 1200 PSIG and centrifuged (20,000 rpm, 30 min, 4°C). The supernatant was loaded onto a 40 cm × 5 cm DEAE-cellulose (Sigma) column at 4°C, and the column was eluted with 1 L buffer A followed by a 2 L linear gradient of 0 to 0.5 M KCl in buffer A. AD-containing fractions were identified by measuring absorbance at 280 nm and by SDS-PAGE analysis. Selected fractions were combined, adjusted to 10 % (g/mL) in ammonium sulfate and loaded onto an 18 cm × 3 cm Butyl-Sepharose column (Sigma) pre-equilibrated with purification buffer containing 10% (g/mL) ammonium sulfate. The column was eluted at 4 °C with 300 mL of buffer A containing 10 % (g/mL) ammonium sulfate followed by a 800 mL linear gradient of 10% (g/mL) to 0% ammonium sulfate in buffer A. The combined AD-containing fractions were reduced in volume to 10 mL using an Amicon device (10 kDa Disc membrane) and then TEV protease was added in a 1:10 molar ratio to cleave the His₆-tag. Following a 15 h incubation period at 4°C, the mixture was loaded onto a 15 cm × 2 cm Ni-NTA column (Sigma) pre-equilibrated with buffer B (5 mM imidazole, 500 mM NaCl, 20

mM Tris, pH 7.5) and eluted with the same buffer. The AD-containing fractions were chromatographed on a Butyl-Sepharose column as described above. The AD-containing fractions were concentrated using an Amicon device (10 kDa Disc membrane) followed by a 10 kDa Macrosep centricon (Pall Filtron) device, and then dialyzed against buffer A. The protein purity was verified by SDS-PAGE analysis. The protein concentration was determined by the Bradford method and by measuring the protein absorbance at 280 nm (extinction coefficient = 55,405 M⁻¹ cm⁻¹). The C424A GIAD mutant was purified as described above for the wild-type enzyme and its purity was verified by SDS-PAGE analysis. The yields of homogeneous GIAD in units of milligrams of protein per gram of wet cells are as follows: wild-type (0.3) and C424A (0.4).

2.4. Functional knockout of the GIAD gene in *G. lamblia*

The GIAD gene was inserted into the plasmid pdsRNA between two opposite tetracycline-inducible Ras-related nuclear GTP-binding protein (*ran*) promoters, and knockout experiments were carried out as described previously [22].

2.5. Determination of AD molecular mass

The AD subunit molecular mass was determined by ESI-MS analysis (University of New Mexico Mass Spectrometry Facility). The mass of the native complex was determined by HPLC size exclusion chromatography/laser light scattering (Yale University) or by FPLC size exclusion chromatography (Superdex 200 Hi-Load 16/60 column) using commercial protein molecular standards.

2.6. GIAD activity assays and steady-state kinetic constant determination

The fixed-time colorimetric assay used for determination of citrulline was adapted from published procedures [23]. Briefly, at a specific time point, an aliquot (250 µL) of the reaction solution was withdrawn and mixed with 1 mL of a mixture of one part oxime reagent (0.8 gm of 2, 3-butanedione 2-oxime in 100 mL of 5 % acetic acid) and two parts of antipyrine/sulfuric acid reagent (5 gm of antipyrine in 1 L of 50 % sulfuric acid). The mixture was placed in a 60 °C water bath for 80 min, after which its absorbance at 466 nm was promptly measured. The continuous spectrophotometric assay used for determination of ammonium ion generated by GIAD-catalyzed L-Arg deimination is based on a reported procedure [24]. Reaction solutions initially contained L-Arg, GIAD, and the coupling system that consists of 1.8 mg/mL glutamate dehydrogenase (bovine liver, type II), 10 mM α-ketoglutarate, and 0.2 mM NADH in 50 mM K⁺HEPES (pH 7.5). The progress of the reaction was monitored at 25 °C by measuring the decrease in the absorbance at 340 nm (ε = 6.22 mM⁻¹ cm⁻¹).

The k_{cat} and K_{m} values were determined by measuring the initial velocity of the AD catalyzed reaction as a function of substrate concentration. The initial velocity data were fitted to Eq. (1) using KinetAsystI.

$$V = V_{\text{max}}[S]/([S] + K_{\text{m}}) \quad (1)$$

where V is the initial velocity, $V_{\max}$ is the maximum velocity, $[S]$ is the substrate concentration and K_m is the Michaelis constant. The k_{cat} value was calculated from the $V_{\max}$ and enzyme concentration ($[E]$) according to the equation $k_{\text{cat}} = V_{\max}/[E]$.

2.7. GIAD pH rate profile determination

The buffers used for pH rate profile determinations are as follows: 25 mM MES and 25 mM acetate (pH 5.0); 50 mM MES (pH 5.6); 50 mM Bis-Tris (pH 6.0 and 6.5); 50 mM HEPES (pH 7.0 and 7.5); 50 mM Tris (pH 8.0); 50 mM TAPS (pH 8.5); CHES (pH 9–9.5); CAPS (pH 10–10.5). Initial velocities of GIAD catalyzed L-Arg deimination were measured at different solution pH values, as a function of L-Arg concentration ($0.5\text{--}10 K_m$), by using the fixed-time colorimetric assay described above. The k_{cat}/K_m values calculated from the initial velocity data were fitted to Eq. (2) for the ionization of an essential acid and the ionization of the protonated form of an essential base.

$$\text{Log}Y = \text{Log}[C/(1+H/K_a+K_b/H)] \quad (2)$$

where Y is the k_{cat} or the k_{cat}/K_m , H is the proton concentration of the reaction buffer, K_a and K_b are the apparent ionization constants of the acidic and basic groups, and C is the constant.

2.8. Single-turnover time course determination by rapid quench

The single turnover reactions (27 μL) of 150 μM GIAD (wild-type or C424A mutant) or 150 μM EcAD (wild-type or C397S mutant) with 10 μM [^{14}C -1]-L-Arg in 50 mM K^+ HEPES (pH 7.5, 25 $^{\circ}\text{C}$) (for GIAD) or 50 mM Bis-Tris (pH 6.0, 25 $^{\circ}\text{C}$)/20 MgCl_2 (for EcAD) were carried out in a KinTek rapid quench instrument. Reaction solutions were quenched with 193 μL of 0.6 M HCl and then vigorously mixed with 60 μL of CCl_4 using a vortex mixer. The mixture was centrifuged at 14,000 rpm for 2 min, the supernatant was removed, and the protein pellet was carefully blotted with a piece of Kimwipe[®] paper. The dried pellet was mixed with 4 mL of scintillation fluid for scintillation counting. The supernatant was transferred to a 5 KD centrifugal filter device (Ultrafree-MC) and centrifuged at 14,000 rpm for 15 min. [^{14}C -1]-L-Citrulline and [^{14}C -1]-L-Arg were separated from the filtrate by high performance liquid chromatography (HPLC). The Beckman ultrasphere ODS reverse column (4.6 mm $\times$ 25 cm, 5 μ) was eluted with a linear gradient of buffer C (25 mM phosphoric acid, 10 mM hexanesulphoric acid, 0.5% (V/V) acetonitrile, pH = 2.5) and buffer D (25 mM phosphoric acid, 10 mM hexanesulphoric acid, 20% (V/V) acetonitrile, pH = 2.5). The gradient program was 100% buffer C for 8 min, 0–100% buffer D for 2 min, hold at 100% buffer D for 10 min, 0–100% buffer C for 1 min, finally hold at 100% buffer D for 9 min. The absorbance of the eluant was monitored at 200 nm. The retention times of L-Arg and L-citrulline standards were 15 min and 9 min, respectively. The [^{14}C -1]-L-arginine and [^{14}C -1]-L-citrulline fractions were analyzed by liquid scintillation counting. Control reactions, for which the acid quench was added to the enzyme before the addition of [^{14}C -1]-L-Arg, were carried out to establish the “background” for radiolabeled enzyme which was typically < 0.4 %. The L-Arg, and L-citrulline time course data were fitted to the first-order rate Eq. (3) and (4), respectively,

$$[S]_t = [S]_{\max} - ([P]_{\max}(1 - e^{-kt})) \quad (3)$$

$$[P]_t = [P]_{\max}(1 - e^{-kt}) \quad (4)$$

where “ k ” is the first-order rate constant; $[S]_t$ and $[P]_t$ are the substrate and product concentrations at time “ t ”. The time course measured for the radiolabeled enzyme was fitted using the simulation program KINSIM [25] and the kinetic model shown in Eq. (5),

where ES is the GIAD complex of [^{14}C -1]-L-Arg, EI is the radiolabeled GIAD and EP is the GIAD complex of [^{14}C -1]-L-citrulline.

2.9. Determination of kinetic constants for AD alternate substrates

The steady-state kinetic constants for AD alternate substrates were measured using the fixed-time colorimetric assay to monitor citrulline formation or the continuous spectrophotometric assay to monitor ammonium ion formation. The k_{cat} and K_m values were determined from initial velocity data as described above.

2.10. Determination of inhibition constants for reversible inhibitors

The reversible inhibition constants K_{ij} and/or K_{is} were determined using the continuous spectrophotometric assay. The 0.5 mL reaction solutions initially contained 50 mM K^+HEPES (pH 7.5), varying concentrations of L-Arg and several fixed concentrations of inhibitor. The competitive inhibition constant K_{is} was determined by fitting the initial velocity data to Eq. (6) with KinetAsystI, and the K_{ij} and K_{is} for mixedtype inhibition were determined by fitting the initial velocity data to Eq. (7) with KinetAsystI.

$$V = V_{\max}[S]/(K_m(1 + [I]/K_{is}) + [S]) \quad (6)$$

$$V = V_{\max}[S]/(K_m(1 + [I]/K_{is}) + [S](1 + [I]/K_{ii})) \quad (7)$$

where V is the initial velocity, $V_{\max}$ is the maximum velocity, $[S]$ is the substrate concentration, K_m is the Michaelis constant, $[I]$ is the inhibitor concentration, K_{is} is the slope inhibition constant, and K_{ii} is the intercept inhibition constant.

2.11. Time and concentration dependent inactivation of GIAD and BcAD

BcAD or GIAD and the inhibitor (*S*-nitroso-L-homocysteine or (*S*)-2-amino-4-(*Z*)-2-cyanoguanidino-butanoic acid) were incubated in 50 mM K^+HEPES (pH 7.0) at 25 °C. At various time points, aliquots (5 μL) were removed and diluted 100-fold into the assay solution (5 mM L-Arg, 1.8 mg/mL glutamate dehydrogenase, 10 mM α -ketoglutarate, and 0.2 mM NADH in 50 mM K^+HEPES at pH 7.0 and 25 °C) to measure remaining AD activity. The *pseudo*-first-order rate constants for the inactivation reactions (k_{obs}) were calculated using Eq. (8),

$$\ln(a_t/a_0) = -k_{\text{obs}}t \quad (8)$$

where a_t is the activity of AD incubated with inhibitor for a specified time (t) and a_0 is the activity of AD incubated in buffer for the same time period.

The binding constant (K_I) and rate constant (k_{inact}) for inactivation were calculated by the k_{obs} values measured as a function of inhibitor concentrations “[I]” to Eq. (9) using Kaleidagraph.

$$k_{\text{obs}} = k_{\text{inact}}[I]/(K_I + [I]) \quad (9)$$

2.12. Reaction of N^{ω} -amino-L-arginine with AD

Inactivation tests with the respective ADs were carried out at 25 °C by incubating N^{ω} -amino-L-arginine (5 mM) and AD (3 μ M) in buffer at the optimal pH. At various time points, aliquots were removed and diluted 100-fold into an activity assay solution (see above) to measure the AD activity. The products formed in the reaction of the AD with the N^{ω} -amino-L-arginine were confirmed by ESI-MS analysis (L-citrulline 176 Da and N -amino-L-citrulline 191 Da) and by HPLC analysis (see separation protocol above; retention times are: 2.5–3 min for hydrazine, 8–9 min for L-citrulline and 14–15 min for N^{ω} -amino-L-arginine). The steady-state kinetic constants k_{cat} and K_m for AD catalyzed hydrolysis of N^{ω} -amino-L-arginine to hydrazine and citrulline were determined by using the colorimetric assay and the steady-state kinetic methods described above.

2.13. Modeling

Molecular modeling, structural alignment and model visualization were carried out with the QUANTA software package (Molecular Simulations Inc.). The three-dimensional model of GLAD was generated based on homology with the PaAD structure (PDB code 2a9g) using the 3D-JIGSAW protein comparative modeling server (<http://bmm.cancerresearchuk.org/~3djigsaw/>) [26]. Several side chains around the substrate-binding site were adjusted manually using the QUANTA rotamer library.

3. Results and Discussion

3.1. RNAi/antisense RNA gene silencing

G. lamblia derives ATP via the glycolytic and ADH pathways [13]. Previously, RNAi/antisense RNA gene-silencing techniques were used to provide evidence that the *G. lamblia* fructose-1, 6-bisphosphate aldolase is essential for trophozoite survival in culture [27]. In the present study, this same method was applied to reduce GLAD levels in cultured trophozoites. As was observed in the fructose-1,6-bisphosphate aldolase knockdown experiment, trophozoites transfected with the silencing plasmid yielded no viable organisms. This finding is consistent with the proposal that GLAD plays a crucial role in *G. lamblia*, and as a result, we conclude that GLAD is a promising candidate for drug targeting.

3.2. Preparation of recombinant GIAD

Key to our planned studies of GIAD catalysis was the preparation of recombinant enzyme. Shortly following the isolation of native GIAD from cultured *G. lamblia* trophozoites reported by Edwards and coworkers in 1997 [12], the protocol for production of the recombinant enzyme in *E. coli* was published [28]. For reasons that are currently unknown, our initial attempts to generate a GIAD producing *E. coli* clone, by using standard expression systems, failed. Ultimately, a maltose binding protein (MBP) fusion construct proved to be effective, and upon removal of the MBP domain soluble, homogenous GIAD was obtained in an adequate yield (0.3 mg/gm wet cells; see SDS-PAGE gel in Fig. 4A).

3.3. Quaternary structures of GIAD and representative bacterial ADs

The first step in characterizing the recombinant GIAD was to determine its subunit mass and its native mass (Table 1). GIAD is unique in that it possesses a 140 amino acid long C-terminal domain. The fold and function of this domain are not known and this caused us to query whether the domain impacts GIAD subunit association. The subunit and native masses reported for *M. arginini* AD (MaAD) [8] and *P. aeruginosa* AD (PaAD) [29] are listed in Table 1 along with the masses determined in this study for *E. coli* AD (EcAD), *B. cereus* AD (BcAD), *B. mallei* (BmAD) and GIAD. EcAD is a monomer, GIAD and MaAD are homodimers, whereas PaAD and BcAD are homotetramers. Crystallographically, MaAD was observed as a dimer [8] whereas the PaAD (shown in Fig. 3B) [29] and BcAD [30] were characterized as dimers of dimer. The GIAD C-terminal domain does not impede formation of the subunit-subunit interface of the dimer. This indicates that the C-terminal domain does not associate with the region of the monomer responsible for dimer formation. It also should be noted that in each AD structure, the substrate-binding site is removed from the subunit interfaces (see Fig. 3B) and, as a result, it is self-contained. This location might account for the catalytically active monomeric form represented by the AD from *E. coli*.

3.4. Construction of a three-dimensional model of the GIAD catalytic domain

So far, attempts to determine the crystal structure of GIAD have not been successful. On the other hand, the reported crystal structures of MaAD, PaAD and BcAD [7,8,30] provided us with structural templates for the construction of a three-dimensional model of the GIAD N-terminal ("catalytic") domain (residues 1–434). The GIAD model, shown in Fig. 5, was generated using the C406A PaAD monomer bound with L-Arg [7] as the modeling template. The model is biased by the structure of the template but, nevertheless, an effective visual aid in the evaluation of the GIAD catalytic and substrate-binding residues. A comparison of the modeled GIAD active site (Fig. 5B) with the active sites of PaAD [7] (shown in Fig. 2A), BcAD [30] and MaAD [8] indicates that all substrate binding and catalytic residues as well as the catalytic scaffold on which they are positioned, are conserved. There is no indication that the entrance of the GIAD active site is less restricted than those of its bacterial counterparts. We make note of this observation in reference to the reported GIAD peptidyl arginine deiminase activity [14], with the caveat that the model might not accurately depict the conformations of the active site gating loops.

3.5. Steady-state kinetic analyses of GIAD catalyzed L-Arg deimination

Given that the GIAD and bacterial ADs catalytic and substrate binding residues are conserved, a common catalytic mechanism is anticipated. However, because these invariant “frontline residues” perform within the context of neighboring residues that are not stringently conserved (identity between some sequence pairs is less than 20%!), the catalytic efficiencies of the ADs will not necessarily be equivalent. Nevertheless, with one exception (MaAD) the steady-state kinetic constants measured at the pH optimum are very similar (see Table 2). On the other hand, the large deviation in the pH range for maximal catalytic activity observed for the ADs is striking. PaAD, BmAD and EcAD for example, are maximally active at pH 5. In contrast, the BcAD is maximally active at pH 7.0 [17]. The GIAD pH rate profiles, on the other hand (see Fig. 4B), define a broad pH range for catalysis. The k_{cat} value for GIAD is maximal from pH 5.5 to pH 9.0 and the k_{cat}/K_m value is maximal between pH 6 and 8. The variation in the AD pH rate profiles might derive from AD specific, pH-sensitive residues that influence the function of the catalytic residues. Also, the different reaction steps catalyzed by AD involve different constellations of pH sensitive ionization states. The extent to which each reaction steps is rate limiting will influence the pH rate profile.

3.6. Rapid quench studies of AD catalyzed single turnover reactions

The rate-limiting step(s) of the GIAD catalysis was investigated by using transient kinetic techniques to measure the apparent rate constant for the formation of the GIAD-Cys424-alkylthiuronium ion intermediate and the apparent rate constant for the hydrolysis of the intermediate to L-citrulline (Fig. 1B). Rapid quench techniques were employed to trap the GIAD-Cys424- $[^{14}\text{C}]$ alkylthiuronium ion intermediate formed during the course of a single turnover reaction of the GIAD($[^{14}\text{C}]$ -L-Arg) complex. The concentrations of $[^{14}\text{C}]$ -L-Arg, $[^{14}\text{C}]$ -L-citrulline and GIAD-Cys424- $[^{14}\text{C}]$ alkylthiuronium ion were measured as a function of reaction time to generate the time courses shown in Fig. 6A and 6B. Control reactions were carried out in parallel using the catalytically inactive C424A GIAD mutant in place of the wild-type GIAD. The $[^{14}\text{C}]$ -L-Arg decay curve and the $[^{14}\text{C}]$ -L-citrulline formation curve were fitted to Eq. (3) and (4), respectively, to define the apparent rate constants $k_{\text{Arg}} = 31 \pm 2 \text{ s}^{-1}$ and $k_{\text{citrulline}} = 27 \pm 2 \text{ s}^{-1}$. Next, the complete data set was fitted using the simulation program KINSIM [25] and the kinetic model shown below in order to define the values of the microscopic rate constants that are reported in Table 3.

The rate constant $k_1 = 80 \text{ s}^{-1}$ actually governs two reaction steps: the first step leads to a tetrahedral intermediate (formed by the addition of the Cys thiolate anion to the L-Arg gaundinium carbon atom) and the second step to the thiuronium ion intermediate (shown in Fig. 1B and represented in the kinetic model). Likewise, the rate constant $k_2 = 35 \text{ s}^{-1}$ governs the step leading from the Cys424-alkylthiuronium ion intermediate to the corresponding tetrahedral intermediate (formed by addition of the activated water molecule at the thiuronium carbon atom) and hence, to L-citrulline. Both rate constants exceed the

steady-state rate constant $k_{\text{cat}} = 2.6 \text{ s}^{-1}$, which indicates that a step or steps (*viz.* a conformational change and/or ligand dissociation) following L-citrulline formation might be rate limiting.

The analogous experiment was carried out with EcAD (see time courses in Fig. 6C and 6D) to define $k_1 = 11.5 \text{ s}^{-1}$ and $k_2 = 5.5 \text{ s}^{-1}$. These values are significantly smaller than the corresponding values determined for GIAD. The kinetic behavior of PaAD [31] is essentially the same as that of EcAD (Table 3). BcAD on the other hand, is a bit more efficient ($k_1 = 50 \text{ s}^{-1}$ and $k_2 = 9 \text{ s}^{-1}$) [30]. For all ADs examined $k_1 > k_2$. Only in the case of the GIAD, is the turnover rate limited by a step that follows L-citrulline formation. This may account, at least in part, for GIAD's uniquely "flat" k_{cat} profile (Fig. 4B).

3.7. In vitro tests of GIAD peptidylarginine deiminase activity

As mentioned above, the model of GIAD suggests that the substrate specificity elements of the bacterial ADs are conserved in the GIAD. Nevertheless, the reported [14] GIAD catalytic activity towards deimination of the side chain of the Arg residue located in the conserved CRGKA cytoplasmic tails of the *G. lamblia* variant-specific surface proteins (VSPs) suggests that GIAD possesses peptidylarginine deiminase activity in addition to its known AD activity. The *in vitro* activity assay, used for the detection of the C-terminal His₆-tagged GIAD (purified from transgenic *G. lamblia* trophozoites) catalyzed deimination of 5 mM His₆-CRGKA, reportedly employed a high reaction temperature (50 °C) in conjunction with a long incubation period (16 h) and an especially sensitive product assay (*viz.* Western blot analysis using an anti-citrulline antibody). Based on the nature of the assay, we suspect that the GIAD catalyzed deimination occurred very slowly. The activity of the recombinant GIAD (50 μM), prepared in *E. coli*, towards Arg-containing peptides as well as the Arg peptide model *N*^α-benzoyl-arginine ethyl ester ("BAEE" which is commonly used to measure PAD activity) was evaluated. Substrate activity was measured by continuously monitoring the formation of ammonia in reaction solutions containing 50 μM GIAD and 10 mM reactant in 50 mM K⁺HEPES (pH 7.5, 25 °C) for 30 min. A single turnover reaction would result in an absorbance change of 0.31 OD. For the peptides RAD, RASD, SFLLRN-NH₂ (C-terminus is O=C-NH₂ instead of COO⁻) and CRGKA no absorbance change was detected and therefore we conclude that the turnover rate must be less than $1 \times 10^{-4} \text{ s}^{-1}$. The same result was obtained for BAEE, even though BAEE was shown by subsequent competitive inhibition studies to bind (albeit weakly) to the GIAD active site ($K_{\text{is}} = 7 \pm 1 \text{ mM}$). For comparison purposes, the reported kinetic constants for human protein arginine deiminase 4-catalyzed BAEE deimination are $k_{\text{cat}} = 6 \text{ s}^{-1}$ and $K_{\text{m}} = 1.4 \text{ mM}$ [32]. Because PAD requires Ca²⁺, GIAD activity towards BAEE was also tested in the presence of 5 mM CaCl₂, but still product formation was not detected. Although it is reasonable to infer from the results of these *in vitro* kinetic determinations that GIAD is not optimized for peptidyl-arginine deiminase activity, the existence of a very slow, yet physiologically relevant deiminase activity directed at the CRGKA cytoplasmic tails of *G. lamblia* VSPs, cannot be dismissed.

3.8. GIAD substrate specificity

The residues that form the L-Arg CH(COO⁻)(NH₃⁺) binding pocket in the bacterial ADs are conserved in the GIAD active site (see Fig. 2A and Fig. 5B). In order to characterize GIAD

substrate specificity, activity tests were carried out with L-Arg analogs modified at the $\text{CH}(\text{COO}^-)(\text{NH}_3^+)$ moiety. Firstly, agmatine (Arg without the $\alpha\text{-COO}^-$), shown in a previous study to have no detectable substrate activity with PaAD [6], was shown in this work to be unreactive with GIAD. Inhibition studies defined agmatine as a very weak, mixed-type inhibitor of GIAD: $K_{\text{is}} = 50 \pm 10 \text{ mM}$ and $K_{\text{ii}} = 120 \pm 20 \text{ mM}$. L-Arginine ethyl ester on the other hand, undergoes GIAD catalyzed deimination ($k_{\text{cat}} = 2.3 \text{ s}^{-1}$ vs 2.6 s^{-1} for L-Arg) but with a significantly increased K_{m} value (2.1 mM vs 0.16 mM for L-Arg). This analog was also tested as a substrate for EcAD and BcAD and no activity was detected. N^α -Benzoyl-arginine too proved to be an active substrate for GIAD ($k_{\text{cat}} = 2.5 \text{ s}^{-1}$, $K_{\text{m}} = 2.3 \text{ mM}$) but not for EcAD or BcAD. These results suggest that GIAD tolerates mono-alkylation (but not di-alkylation as in BAEE) at the $\text{CH}(\text{COO}^-)(\text{NH}_3^+)$ units, whereas its bacterial counterparts do not. Thus, despite the perceived similarity of AD substrate binding sites, something is clearly unique about the GIAD site, too subtle to glean from the model, but nevertheless significant enough to cause a small change in the substrate specificity.

L-Homoarginine (L-Arg with one additional CH_2 unit) is not a GIAD substrate (nor a substrate for the bacterial ADs [33,34]) but rather a weak binding competitive inhibitor ($K_{\text{is}} = 48 \pm 6 \text{ mM}$). Together, these substrate screening results provide a guide to the design of mechanism-based inhibitors (see below), and suggest the requirement that these inhibitors possess a $\text{L-CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{COO}^-)(\text{NH}_3^+)$ unit to insure effective active site targeting.

3.9. Investigation of AD inhibition by active site directed L-Arg analogs

Two designs of Cys-directed GIAD covalent inhibitors are illustrated in Fig. 7A and 7B. One involves the use of an Arg analog to deliver an electrophilic “warhead” to the active site Cys424 nucleophile (Fig. 7A). The other employs an Arg analog, modified at the guanidinium moiety, that will undergo the first partial reaction but not the second (see Fig. 7B). Both inhibitor designs are based on earlier studies of mechanism-based inhibitors of the Cys protease papain.

The first inhibitor explored is *S*-nitroso-L-homocysteine (Fig. 7C). This compound has previously been shown to modify protein Cys residues, most notably those of mammalian DDAHs, by nitrosylation and/or by formation of the corresponding *N*-thiosulfoximide adduct [35,36]. Accordingly, *S*-nitroso-L-homocysteine ($2\text{--}90 \text{ mM}$) and GIAD ($10 \text{ }\mu\text{M}$) were incubated in $50 \text{ mM K}^+\text{HEPES}$ ($\text{pH } 7.5$, $25 \text{ }^\circ\text{C}$). Aliquots were removed, after various incubation periods, for GIAD activity determination. The value of k_{obs} for inactivation was determined from the slope of the plot of the percent remaining GIAD activity vs. incubation time (Fig. 8A). The curvature observed in the plot of k_{obs} vs. *S*-nitroso-L-homocysteine concentration (Fig. 8B) indicates a two-step inactivation sequence in which the binding of *S*-nitroso-L-homocysteine to GIAD is followed by covalent modification. The inactivation constants $K_{\text{I}} = 40 \pm 10 \text{ mM}$ and $k_{\text{inact}} = 0.17 \pm 0.02 \text{ min}^{-1}$ were determined by data fitting to Eq. (9). The activity of GIAD was not regained following dialysis for 10 h. This finding indicates that irreversible inhibition has taken place. On the other hand, the covalent adduct formed by incubation of $10 \text{ }\mu\text{M}$ GIAD with $10 \text{ mM S-nitroso-L-homocysteine}$ in $50 \text{ mM K}^+\text{HEPES}$ ($\text{pH } 7.0$, $25 \text{ }^\circ\text{C}$) for 1 h was not detected by ESI-MS analysis. We therefore turned our attention to the bacterial ADs in hope that the *S*-nitroso-L-homocysteine derived

Cys-adduct formed using one of these might survive ionization in the mass spectrometer. The inactivation data observed for BcAD (Fig. 8C and 8D) are similar to those determined for GIAD (Fig. 8A and 8B) and they define the inactivation constants $K_I = 66 \pm 30$ mM and $k_{\text{inact}} = 1.0 \pm 0.3 \text{ min}^{-1}$. The ESI-MS spectrum of the inactivated (24 μM enzyme incubated 30 min with 10 mM *S*-nitroso-L-homocysteine in 50 mM K^+ HEPES pH 7.0, 25 $^\circ\text{C}$) BcAD (native mass 46638 Da) showed peaks at 46968 Da (+30 Da), 46998 Da (+60 Da), 47027 Da (+88 Da), 47131 Da (+193 Da) and 47162 Da (+224 Da). Apparently, all three BcAD cysteine residues (each solvent accessible) [30] are subject to modification to form the corresponding *S*-nitroso adduct (+29 Da) or the *N*-thiosulfoximide adduct (+164 Da) (pictured in Fig. 7C).

In contrast to GIAD and BcAD, *S*-nitroso-L-homocysteine inactivation of DDAH is reported to follow second order kinetics ($k = 4 \text{ M}^{-1} \text{ s}^{-1}$ [35]; $k = 9 \text{ M}^{-1} \text{ s}^{-1}$ [37]). X-ray crystallographic analysis of inactivated DDAH showed that the active site Cys undergoes *N*-thiosulfoximide adduct formation and that the surface Cys residue undergoes *S*-nitrosylation [38].

Even though GIAD (and BcAD) binds *S*-nitroso-L-homocysteine at the active site, the binding is weak compared to substrate binding. This is because, without the guanidinium group of the L-Arg, the favorable ligand binding energy derived from hydrogen bond interaction with Asp175 and Asp282 and ion pair formation with the Cys424 thiolate anion is lost (see Fig. 4B). In order to saturate the active site a high concentration of *S*-nitroso-L-homocysteine is required and this, in turn, is expected to enhance the rate of collision-based reactions of surface Cys residues. Furthermore, at pH 7.0, the Cys-thiol is protonated. Bound L-Arg dramatically reduces the pK_a of the AD active site Cys-thiol so that it is ionized for nucleophilic addition [17]. Because the *S*-nitroso group of the *S*-nitroso-L-homocysteine ligand is not positively charged, we anticipate that its binding will not cause a large reduction in the pK_a of the active site Cys-thiol. Consequently, the protonation state of the active site Cys-thiol might not differ dramatically from those of the surface Cys-thiols. Because BcAD possesses two surface Cys residues [30], it is therefore not surprising that all three BcAD Cys residues are were modified by the *S*-nitroso-L-homocysteine.

Attention was next directed to the L-Arg analog (*S*)-2-amino-4-(*Z*)-2-cyanoguanidino-butanoic acid (N^0 -cyano-L-Arg; Fig. 7D). The results from previous work had shown that peptide analogs functionalized with a cyano group inhibit papain via formation of the corresponding thioimide adducts [39–42]. Thus, one possible pathway for N^0 -cyano-L-Arg induced GIAD inactivation is nucleophilic attack of the GIAD Cys-residue on the cyano carbon to form the conjugated covalent adduct depicted in Fig. 7D. Alternatively, nucleophilic addition of the GIAD Cys-thiolate anion at the guanidinium carbon, followed by loss of ammonium ion might lead to a dead-end Cys-thioureido adduct (Fig. 7D). When N^0 -cyano-L-Arg (40 mM) was tested as a GIAD inhibitor neither reversible nor irreversible inhibition was observed. On the other hand, incubation of BcAD (6 μM) with varying concentrations of N^0 -cyano-L-Arg (0–40 mM) resulted in time- and concentration-dependent loss of enzyme activity (Fig. 8E and F). The pseudo-first order rate constants of inactivation (k_{obs}), determined for each inhibitor concentration, are plotted in Fig. 8F to show that the value of k_{obs} increases with increasing inhibitor concentrations until BcAD

becomes saturated. The data were fitted to obtain the k_{inact} and K_I values of $0.15 \pm 0.04 \text{ min}^{-1}$ and $20 \pm 10 \text{ mM}$, respectively. The inactivation was found to be irreversible by employing overnight dialysis against 50 mM K^+ HEPES/1 mM DTT at pH 7.5 and 4 °C. However, analysis of the inactivated enzyme by ESI-MS failed to detect the modified enzyme and therefore, the structural basis for inactivation is not known nor is the reason why N^0 -cyano-L-Arg inactivates BcAD but not GIAD.

The reaction between GIAD and N^0 -amino-L-arginine (N^0 -amino-L-Arg) was examined next. Two possible reaction pathways can be envisioned (Fig. 7E). One of these leads to loss of ammonia with the formation of the corresponding N^0 -amino substituted Cys-alkylthiuronium ion adduct and the other to loss of hydrazine and the formation of the authentic Cys-alkylthiuronium ion intermediate. GIAD was preincubated with 10 mM N^0 -amino-L-Arg, and then assayed for L-Arg deiminase activity. No activity reduction was observed to occur over a 1 h preincubation period. The same result was obtained for EcAD, BmAD and BcAD. On the other hand, N^0 -amino-L-Arg proved to be an active substrate. Product analysis using HPLC and mass spectral techniques, in conjunction with citrulline and N^0 -amino-L-citrulline chemical standards (see Materials and Methods for details), showed that the reaction pathway catalyzed by each of the ADs proceeds with the displacement of hydrazine rather than ammonia. Thus, productive binding places the hydrazine substituent in the leaving group binding pocket (see Fig. 2A and 4B). The steady-state kinetic constants measured for AD catalyzed N^0 -amino-L-Arg hydrolysis reported in Table 4, indicate that the N^0 -amino substituent increases the substrate's K_m value but does not decrease its k_{cat} value. Even though the N^0 -amino-L-Arg is a substrate rather than an inhibitor it still might be used against *G. lamblia* trophozoites because the hydrazine that is produced by the AD *in situ* is potentially toxic.

4. Conclusion

The studies described above have provided insight into GIAD structure and function. Based on the results of the GIAD gene knockdown experiment, GIAD appears to be a viable candidate for drug development. Moreover, the GIAD catalytic Cys is an obvious target for an active site directed electrophile or a suicide substrate. Nevertheless, the GIAD active site poses challenging requirements for successful lead-inhibitor design. Firstly, because the ionization of the catalytic Cys-thiol is substrate assisted, the inhibitor must likewise induce Cys-thiol ionization. Secondly, because the substrate-binding is based on multiple polar interactions (which includes ion pair formation) within a spatially confined binding site, the inhibitor must also possess strategically placed, and sized, polar substituents.

Acknowledgements

The pDEST-MBP vector was a generous gift from Dr. D. S. Waugh and the N^0 -Amino-L-citrulline was a gift from Dr. S. Bruce King.

Abbreviations

AD arginine deiminase

GMSF	guanidino-group modifying enzyme superfamily
IPTG	isopropyl- β -D-thiogalactopyranoside
DTT	dithiothreitol
NADH	the reduced form of nicotinamide-adenine dinucleotide
MES	2-(<i>N</i> -morpholino)ethanesulfonic acid
Bis-Tris	[bis(2-hydroxyethyl)amino]tris-(hydroxymethyl)methane
HEPES	<i>N</i> -(2-hydroxyethyl)-piperazine- <i>N'</i> -2-ethanesulfonic acid
Tris	tris(hydroxymethyl) aminomethane
TAPS	3-[[tris(hydroxymethyl)methyl]amino]propanesulfonic acid
CHES	2-(<i>N</i> -cyclohexylamino)ethanesulfonic acid
CAPS	3-(cyclohexylamino)-propanesulfonic acid
GIAD	<i>Giardia lamblia</i> arginine deiminase
PaAD	<i>Pseudomonas aeruginosa</i> arginine deiminase
EcAD	<i>Escherichia coli</i> arginine deiminase
BmAD	<i>Burkholderia mallei</i> arginine deiminase
BcAD	<i>Bacillus cereus</i> arginine deiminase
PAD	peptidylarginine deiminase
AgD	agmatine deiminase
DDAH	N^0 , N^0 -dimethylarginine dimethylamidohydrolase
PaDDAH	<i>Pseudomonas aeruginosa</i> N^0 , N^0 -dimethylarginine dimethylamidohydrolase

References

1. Zuniga M, Perez G, Gonzalez-Candelas F. Mol. Phylogenet. Evol. 2002; 25:429–444. [PubMed: 12450748]
2. Cunin R, Glansdorff N, Pierard A, Stalon V. Microbiol. Rev. 1986; 50:314–352. [PubMed: 3534538]
3. Shirai H, Blundell TL, Mizuguchi K. Trends Biochem. Sci. 2001; 26:465–468. [PubMed: 11504612]
4. Nakada Y, Itoh Y. Microbiology. 2003; 149(Pt 3):707–714. [PubMed: 12634339]
5. Llacer JL, Polo LM, Tavaréz S, Alarcon B, Hilario R, Rubio V. J. Bacteriol. 2007; 189:1254–1265. [PubMed: 17028272]
6. Lu X, Li L, Wu R, Feng X, Li Z, Yang H, Wang C, Guo H, Galkin A, Herzberg O, Mariano PS, Martin BM, Dunaway-Mariano D. Biochemistry. 2006; 45:1162–1172. [PubMed: 16430212]
7. Galkin A, Lu X, Dunaway-Mariano D, Herzberg O. J. Biol. Chem. 2005; 280:34080–34087. [PubMed: 16091358]
8. Das K, Butler GH, Kwiatkowski V, Clark AD Jr, Yadav P, Arnold E. Structure. 2004; 12:657–667. [PubMed: 15062088]
9. Murray-Rust J, Leiper J, McAlister M, Phelan J, Tilley S, Santa Maria J, Vallance P, McDonald N. Nat. Struct. Biol. 2001; 8:679–683. [PubMed: 11473257]

10. Stone EM, Person MD, Costello NJ, Fast W. *Biochemistry*. 2005; 44:7069–7078. [PubMed: 15865451]
11. Arita K, Hashimoto H, Shimizu T, Nakashima K, Yamada M, Sato M. *Nat. Struct. Mol. Biol.* 2004; 11:777–783. [PubMed: 15247907]
12. Knodler LA, Schofield PJ, Gooley AA, Edwards MR. *Exp. Parasitol.* 1997; 85:77–80. [PubMed: 9024204]
13. Adam RD. *Clin. Microbiol. Rev.* 2001; 14:447–475. [PubMed: 11432808]
14. Touz MC, Ropolo AS, Rivero MR, Vranich CV, Conrad JT, Svard SG, Nash TE. *J. Cell Sci.* 2008; 121:2930–2938. [PubMed: 18697833]
15. Palm JE, Weiland ME, Griffiths WJ, Ljungstrom I, Svard SG. *J. Infect. Dis.* 2003; 187:1849–1859. [PubMed: 12792861]
16. Ringqvist E, Palm JE, Skarin H, Hehl AB, Weiland M, Davids BJ, Reiner DS, Griffiths WJ, Eckmann L, Gillin FD, Svard SG. *Mol. Biochem. Parasitol.* 2008; 159:85–91. [PubMed: 18359106]
17. Li L, Li Z, Wang C, Xu D, Mariano PS, Guo H, Dunaway-Mariano D. *Biochemistry*. 2008; 47:4721–4732. [PubMed: 18366187]
18. Stamler, JS.; Feelisch, M. *Methods in Nitric Oxide Research*. Chichester: John Wiley & Sons Ltd.; 1996. p. 521–539.
19. Wagenaar FL, Kerwin JF. *J. Org. Chem.* 1993; 58:4331–4338.
20. Keister DB. *Trans. R. Soc. Trop. Med. Hyg.* 1983; 77:487–488. [PubMed: 6636276]
21. Nallamsetty S, Austin BP, Penrose KJ, Waugh DS. *Protein Sci.* 2005; 14:2964–2971. [PubMed: 16322578]
22. Touz M, Kulakova T, Nash TE. *Mol. Biol. Cell.* 2004; 15:3053–3060. [PubMed: 15107467]
23. Prescott LM, Jones ME. *Anal. Biochem.* 1969; 32:408–419. [PubMed: 5361395]
24. Weickmann JL, Fahrney DE. *J. Biol. Chem.* 1977; 252:2615–2620. [PubMed: 856796]
25. Barshop BA, Wrenn RF, Frieden C. *Anal. Biochem.* 1983; 130:134–145. [PubMed: 6688159]
26. Bates PA, Kelley LA, MacCallum RM, Sternberg MJ. *Proteins Suppl.* 2001; 5:39–46.
27. Galkin A, Kulakova L, Melamud E, Li L, Wu C, Mariano P, Dunaway-Mariano D, Nash TE, Herzberg O. *J. Biol. Chem.* 2007; 282:4859–4867. [PubMed: 17166851]
28. Knodler LA, Sekyere EO, Stewart TS, Schofield PJ, Edwards MR. *J. Biol. Chem.* 1998; 273:4470–4477. [PubMed: 9468500]
29. Galkin A, Kulakova L, Sarikaya E, Lim K, Howard A, Herzberg O. *J. Biol. Chem.* 2004; 279:14001–14008. [PubMed: 14701825]
30. Li L, Li Z, Chen D, Lu X, Feng X, Wright EC, Solberg NO, Dunaway-Mariano D, Mariano PS, Galkin A, Kulakova L, Herzberg O, Green-Church KB, Zhang L. *J. Am. Chem. Soc.* 2008; 130:1918–1931. [PubMed: 18205354]
31. Lu X, Galkin A, Herzberg O, Dunaway-Mariano D. *J. Am. Chem. Soc.* 2004; 126:5374–5375. [PubMed: 15113205]
32. Kearney PL, Bhatia M, Jones NG, Yuan L, Glascock MC, Catchings KL, Yamada M, Thompson PR. *Biochemistry*. 2005; 44:10570–10582. [PubMed: 16060666]
33. Shibatani T, Kakimoto T, Chibata I. *J. Biol. Chem.* 1975; 250:4580–4583. [PubMed: 237904]
34. Smith DW, Ganaway RL, Fahrney DE. *J. Biol. Chem.* 1978; 253:6016–6020. [PubMed: 681336]
35. Hong L, Fast W. *J. Biol. Chem.* 2007; 282:34684–34692. [PubMed: 17895252]
36. Knipp M, Braun O, Vasak M. *J. Am. Chem. Soc.* 2005; 127:2372–2373. [PubMed: 15724974]
37. Braun O, Knipp M, Chesnov S, Vasak M. *Protein Sci.* 2007; 16:1522–1534. [PubMed: 17600152]
38. Frey D, Braun O, Briand C, Vasak M, Grutter MG. *Structure*. 2006; 14:901–911. [PubMed: 16698551]
39. Brisson JR, Carey PR, Storer AC. *J. Biol. Chem.* 1986; 261:9087–9089. [PubMed: 3722189]
40. Liang TC, Abeles RH. *Arch. Biochem. Biophys.* 1987; 252:626–634. [PubMed: 3813553]
41. Dufour E, Storer AC, Menard R. *Biochemistry*. 1995; 34:9136–9143. [PubMed: 7619812]
42. Reddy SY, Kahn K, Zheng YJ, Bruice TC. *J. Am. Chem. Soc.* 2002; 124:12979–12990. [PubMed: 12405824]

A**Arginine deiminase** **Agmatine deiminase** **Dimethylarginine dimethylaminohydrolase** **Peptidylarginine deiminase** **B** **Fig. 1.**

A. Reactions catalyzed by AD, AgD, DDAH and PAD. **B.** Common reaction mechanism observed for AD ($\text{R} = \text{H}$, $\text{R}' = \text{L-CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{COO}^-)(\text{NH}_3^+)$), AgD ($\text{R} = \text{H}$, $\text{R}' = \text{CH}_2\text{CH}_2\text{CH}_2\text{CH}_2(\text{NH}_3^+)$), DDAH ($\text{R} = \text{CH}_3$, $\text{R}' = \text{L-CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{COO}^-)(\text{NH}_3^+)$) and PAD ($\text{R} = \text{H}$, $\text{R}' = \text{L-CH}_2\text{CH}_2\text{CH}_2\text{CH}(\text{COOEt})(\text{NHbz})$).

Fig. 2.

Backbone fold with catalytic scaffold colored (left) and stereodiagram of substrate-binding and catalytic residues, each color coded to coordinate with the color of its locus on the catalytic scaffold (right) for (A) C406A PaAD complexed with L-Arg (PDB ID 2A9G) with a Cys side chain modeled in place of the Ala406 side chain, (B) C249S PaDDAH bound with L- N^0 , N^0 -dimethylarginine (PDB ID 1H70), (C) AgDI with the carbon atom of the guanidium group of agmatine bonded to the carbon atom of Cys357 (PDB ID 2JER) and (D) PAD H4 bound with Histone 3 N-terminal tail including Arg (PDB ID 2DEW). Ligands

are shown in stick representation with carbon atoms colored black, oxygen atoms red and nitrogen atoms blue.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Fig. 3.

A PaAD (PDB ID 2A9G) backbone modeled with the Histone 3 N-terminal tail ligand (shown in stick representation with carbon atoms colored green, nitrogen blue and oxygen red) from the PAD H4 structure (PDB ID 2DEW). The PaAD loop (residue 27–41) that clashes with the ligand is colored red. **B.** The C406A PaAD tetramer (PDB ID 2A9G) in which the magenta and blue colored subunits represent one dimer unit and the green and yellow colored subunits represent the other dimer unit. The Arg ligand is shown in stick representation with carbon atoms colored black, nitrogen atoms blue and oxygen atoms red.

Fig. 4.

A. SDS-PAGE gel of purified recombinant GIAD shown in the right lane and protein molecular weight standards shown in the left lane. **B.** The k_{cat} (○) and k_{cat}/K_m (●) pH profiles for GIAD catalyzed L-Arg deimination. The k_{cat}/K_m profile data were fitted with Eq. (2). The acid range data defined an apparent $\text{pK}_a = 4.3$.

A **B** **Fig. 5.**

A. Superposition of the GLAD model (green) and the structure of the C406A PaAD(L-Arg) complex (PDB ID 2A9G) (red). The L-arginine ligand shown in black stick representation.

B. Stereodigram of the active site residues of the modeled GLAD(L-Arg) with carbon atoms colored grey, oxygen atoms red and nitrogen atoms blue.

Fig. 6.

Time courses for the single turnover reaction of 10 μM [^{14}C -1]-L-Arg catalyzed by 150 μM GlAD (wild-type or C397S mutant) in 50 mM K^+HEPES (pH 7.5, 25 $^\circ\text{C}$) or 150 μM EcAD (wild-type or C424A) in 50 mM Bis-Tris (pH 6.0)/20 MgCl_2 . **A.** GlAD time courses: [^{14}C -1]-L-arginine (●) and [^{14}C -1]-L-citrulline (○). **B.** GlAD time courses: [^{14}C]-labeled wild-type GlAD (●) and (○)[^{14}C]-labeled C424A AD. **C.** EcAD time courses: [^{14}C -1]-L-arginine (●) and [^{14}C -1]-L-citrulline (○). **D.** EcAD time courses: [^{14}C]-wild-type EcAD (●) and (○)[^{14}C]-labeled C397S EcAD.

Fig. 7.

Schemes depicting the reaction of the GIAD Cys424 with (A) a L-Arg analog carrying an electrophilic “warhead”, (B) a L-Arg analog modified with a group “Y” that blocks the hydrolysis partial reaction, (C) *S*-nitroso-L-homoseine, (D) *N*^ω-cyano-L-Arg and (E) *N*^ω-amino-L-Arg.

A

B

C

D

Fig. 8.

Time- and concentration-dependent inactivation of *S*-nitroso-L-homocysteine to GIAD (10 μ M) at pH 7.5, 50 mM HEPES and 25°C. (A) Plot of $\ln(v_t/v_0)$ vs. time. 2 mM ($\diamond$), 5 mM ($\blacklozenge$), 10 mM ($\square$), 30 mM($\blacksquare$), 60 mM ($\circ$), and 90 mM ($\bullet$) of *S*-nitroso-L-homocysteine. (B) Plot of k_{obs} vs. *S*-nitroso-L-homocysteine concentration with data fitted to the Eq. (9) to obtain K_I and k_{inact} values. Time and concentration dependence of the inactivation of BcAD (12 μ M) by *S*-nitroso-L-homocysteine in 50 mM K⁺HEPES at pH 7.0 and 25 °C. (C) Plot of $\ln(v_t/v_0)$ vs time. 2 mM ($\diamond$), 5 mM ($\blacklozenge$), 10 mM ($\square$), 25 mM ($\blacksquare$) and 50 mM ($\circ$) *S*-nitroso-

L-homocysteine. **(D)** Plot of k_{obs} vs *S*-nitroso- L-homocysteine concentration with data fitting to Eq. (9). Time and concentration dependence of the inactivation of BcAD by *N*⁰-cyano-L-Arg in 50 mM K⁺HEPES at pH 7.0 and 25 °C. **(E)** Plot of $\ln(v_t/v_o)$ vs time. 0 mM ($\diamond$), 5 mM ($\blacklozenge$), 10 mM ($\square$), 20 mM ($\blacksquare$) and 40 mM ($\circ$) *N*⁰-cyano-L-Arg. **(F)** Plot of k_{obs} vs *N*⁰-cyano-L-Arg concentration with data fitting to Eq. (9).

Table 1

AD Subunit Size and Quaternary Structure.

AD	MW calculated (Da)	MW mass spec (Da)	Native MW (kDa)	Quaternary Structure
Ec	45902	45901	43	monomer
Bm	46052	45921 ^a	168	tetramer
Gl	64189	64190	127	dimer
Pa ^b	46436	46305 ^a	180	tetramer
Bc	46938	46938	159	tetramer
Ma ^c	43915	43900	not reported	dimer

^a For the BmAD and PaAD, the difference between the calculated and experimental mass is 131 Da, which indicates that the N-terminal Met is removed by posttranslational modification.

^b Reported in reference [6].

^c Reported in reference [8].

Table 2

Comparison of the steady-state kinetic constants for AD-catalyzed conversion of L-arginine to L-citrulline plus ammonia measured at the pH optimum and 25 °C.

AD	pH	k_{cat} (s ⁻¹)	K_{m} (mM)	$k_{\text{cat}}/K_{\text{m}}$ (M ⁻¹ s ⁻¹)
GlAD	7.5	2.6 ± 0.1	0.16 ± 0.01	1.6 × 10 ⁴
BcAD ^a	7.0	4.4 ± 0.1	0.09 ± 0.01	4.9 × 10 ⁴
PaAD ^a	5.6	6.3 ± 0.1	0.14 ± 0.01	4.5 × 10 ⁴
BmAD ^a	5.6	1.3 ± 0.1	0.09 ± 0.01	1.4 × 10 ⁴
EcAD ^a	6.0	3.2 ± 0.1	0.32 ± 0.02	1.0 × 10 ⁴
MaAD ^b	7.2	29	0.004	7 × 10 ⁶

^a Reported in reference [17].

^b *Mycoplasma arthritidis* reported in reference [34].

Microscopic rate constants extracted from time course data measured for AD catalyzed single turnover of [¹⁴C-1]-L-Arg using KINSIM [25] and the kinetic model:

Table 3

AD	pH	k ₁ (s ⁻¹)	k ₋₁ (s ⁻¹)	k ₂ (s ⁻¹)	k ₋₂ (s ⁻¹)
GIAD ^a	7.5	80	0.1	35	0.5
EcAD ^b	6.0	11.5	0.5	5.5	0.15
PaAD ^c	5.6	13	0.05	6.5	0.02
BcAD ^d	7.0	50	0.1	9	0.1

^aReaction of 150 μM GIAD with 10 μM [¹⁴C-1] L-Arg at pH 7.5 and 25 °C.

^bReaction of 150 μM EcAD with 10 μM [¹⁴C-1] L-Arg at pH 6.0 and 25 °C.

^cReaction of 520 μM PaAD with 10 mM [¹⁴C-1] L-Arg at pH 5.6 and 25 °C [31].

^dReaction of 104 μM BcAD with 49 mM [¹⁴C-1] L-Arg at pH 7.0 and 25 °C [30].

Table 4

The steady-state kinetic constants of AD catalyzed hydrolysis of *N*⁶-amino-L-arginine to hydrazine and L-citrulline.

AD	pH	k_{cat} (s ⁻¹)	K_{m} (μM)	$k_{\text{cat}}/K_{\text{m}}$ (M ⁻¹ s ⁻¹)
EcAD	6.0	1.0 ± 0.1	10 ± 2	1.0 × 10 ²
BmAD	5.6	3.0 ± 0.2	90 ± 10	3.3 × 10 ¹
GlAD	7.5	0.58 ± 0.04	2.0 ± 0.4	2.9 × 10 ²
PaAD ^a	5.6	7 ± 2	50 ± 20	1.4 × 10 ²
BcAD	7.0	0.44 ± 0.02	7 ± 1	6.3 × 10 ¹

^a Reported in reference [6].